Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats.

Netrebenko AS, Gureev VV, Pokrovskii MV, Gureeva AV, Tsuverkalova YM, Rozhkov IS

Archives of Razi Institute31 Oct 2021Cited by 4 (Europe PMC)

PMID35096335PMCIDPMC8791007DOI10.22092/ari.2021.355849.1728PepBankPUB-35096335

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, pHBSP and infliximab together had a pronounced nephroprotective effect as compared with erythropoietin; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, pHBSP and infliximab protected the kidney more than erythropoietin did; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
Not applicableNephroprotective effect compared with erythropoietin
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Comparator
Recombinant erythropoietin
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
1 context sentence(design, population, supporting numbers)
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633501
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, blood creatinine decreased significantly after treatment with pHBSP and infliximab; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, blood creatinine, a kidney damage marker, fell after pHBSP and infliximab; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
DecreasePlasma creatinine
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
2 context sentences(design, population, supporting numbers)
Summary · context
There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion.
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633502
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, blood urea decreased significantly after treatment with pHBSP and infliximab; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, blood urea, a kidney damage marker, fell after pHBSP and infliximab; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
DecreasePlasma urea
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
2 context sentences(design, population, supporting numbers)
Summary · context
There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion.
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633503
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, kidney microcirculation improved after treatment with pHBSP and infliximab; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, blood flow in the kidney improved after pHBSP and infliximab; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseKidney microcirculation
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
2 context sentences(design, population, supporting numbers)
Summary · context
There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion.
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633504
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, glomerular filtration rate normalized after treatment with pHBSP and infliximab; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, kidney filtration rate returned to normal after pHBSP and infliximab; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
IncreaseGlomerular filtration rate
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
2 context sentences(design, population, supporting numbers)
Summary · context
There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion.
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633505
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with renal ischemia-reperfusion injury, fractional sodium excretion normalized after treatment with pHBSP and infliximab; the abstract does not separate the two drugs.
In plain wordsIn rats with kidney injury, sodium excretion returned to normal after pHBSP and infliximab; the results are not split by drug.
Peptide
Cibinetide (ARA-290)
Outcome
Direction not reportedFractional sodium excretion
Study
ratn: not reported in source
Wistar rats with renal ischemia-reperfusion injury
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of pHBSP and infliximab to the animals with ischemia-reperfusion kidney injury has a pronounced nephroprotective effect, as compared to erythropoietin.
2 context sentences(design, population, supporting numbers)
Summary · context
There was a significant decrease in blood levels of creatinine and urea, improvement of microcirculation in the kidney, normalization of glomerular filtration rate, and fractional sodium excretion.
Summary · context
The experiment was performed on 70 white male Wistar laboratory rats which received recombinant erythropoietin, pHBSP, and infliximab.
Report a problemFND-3509633506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.